Connect Biopharma announced that, on November 28, it received a letter from the Listings Qualifications Department of the Nasdaq indicating that, for the last 30 consecutive business days, the bid price for the company’s American depositary shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5550.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CNTB:
- Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
- Connect Biopharma To Present at Upcoming Investor and Scientific Conferences
- CORRECTING and REPLACING — Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
